首页 | 本学科首页   官方微博 | 高级检索  
     检索      

高危非致残性脑血管病——强化治疗的新方向
引用本文:王伊龙,贾茜,王拥军.高危非致残性脑血管病——强化治疗的新方向[J].科技导报(北京),2017,35(4):31-35.
作者姓名:王伊龙  贾茜  王拥军
作者单位:首都医科大学附属北京天坛医院神经内科, 北京 100050
基金项目:国家科技支撑计划项目(2011BAI08B02);国家重点研发计划项目(2016YFC0901000)
摘    要: 脑血管病是中国居民死亡率最高的疾病,同时也是引起成人致残的最主要原因之一,其中高危非致残性脑血管病以其临床最常见、病情早期不稳定、复发风险高、及时治疗获益大等特点,近年来逐渐受到广泛关注。本项目组10余年来一直致力于寻找脑血管病的最佳干预人群、创新优化抗栓治疗方案、探寻个体化治疗新方法等,本文结合项目组取得的一系列研究结果,从高危非致残性脑血管病的早期高效识别、有效强化治疗新方案、个体化精准治疗新策略3方面内容对该类型脑血管病进行综述。

关 键 词:脑血管事件  治疗  抗栓治疗  
收稿时间:2016-12-01

High-risk non-disabling ischemic cerebrovascular events (HR-NICE): A new target for aggressive treatment
WANG Yilong,JIA Qian,WANG Yongjun.High-risk non-disabling ischemic cerebrovascular events (HR-NICE): A new target for aggressive treatment[J].Science & Technology Review,2017,35(4):31-35.
Authors:WANG Yilong  JIA Qian  WANG Yongjun
Institution:Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China
Abstract:The cerebrovascular disease is the most common cause for death or adult disability among Chinese population. The High-Risk Non-Disabling Ischemic Cerebrovascular Events (HR-NICE) are very common, and they are unstable in early phases, with good prognosis after effective treatment. In recent years, the HR-NICE has gradually attracted worldwide attentions. Our work has focused on the patients with the highest stroke risk, the most effective antithrombotic therapy, and the most appropriate individualized treatment for more than 10 years. In this paper, we review the early recognition, the diagnosis and the treatment of the HR-NICE.
Keywords:cerebrovascular event  treatment  anti-thrombotic agent  
本文献已被 CNKI 等数据库收录!
点击此处可从《科技导报(北京)》浏览原始摘要信息
点击此处可从《科技导报(北京)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号